26993-32-8

Usage

Uses

Used in Organic Synthesis:
(2E)-2-Hexadecen-1-ol is used as a synthetic building block for the creation of various organic compounds. Its alkenol structure allows for a wide range of chemical reactions, making it a versatile starting material in the synthesis of complex organic molecules.
Used in Chemical Industry:
In the chemical industry, (2E)-2-Hexadecen-1-ol is used as an intermediate in the production of various chemicals, including fragrances, pharmaceuticals, and agrochemicals. Its unique structure and reactivity contribute to the development of new and innovative products.
Used in Research and Development:
(2E)-2-Hexadecen-1-ol is also utilized in research and development for the study of its chemical properties and potential applications. Its use in this context helps to expand the understanding of organic chemistry and the development of new synthetic methods and techniques.

Upstream product

• 765-09-3 1-bromotridecane 
• 112-72-1 1-Tetradecanol 
• 135251-95-5 (2E)-ethyl 2-hexadecenoate 
• 304-59-6 Rochelle's salt 
• 51534-33-9 1t,3-bis-methylsulfanyl-hexadec-1-ene 
• 124-25-4 myristylaldehyde 
• 2833-99-0 n-2-hexadecyn-1-ol 
• 50-00-0 formaldehyd 
• 765-13-9 pentadec-1-yne 
• 3163-37-9 (E)-hexadec-2-enal 

Downstream Products

• 2673-72-5 (2S,3R,E)-2-aminooctadec-4-ene-1,3-diol hydrochloride 
• 536-14-1 N-palmitoyl-D-erythro-sphingomyelin 
• 126624-40-6 (2R,4E)-2-N-hexadecanoylamino-4-octadecen-1-ol 

Relevant academic research and scientific papers

NOVEL SYNTHESIS INTERMEDIATES FOR OBTAINING DERIVATIVES OF SPHINGOSINES, CERAMIDES AND SPHINGOMYELINS WITH GOOD YIELDS

The subject matter of the present invention is the novel molecules of formulae E, E′ and F. These molecules prove to be synthesis intermediates that are very advantageous for the manufacture of derivatives of sphingosine or of ceramides functionalized in position 1, with good yields, in which R1 and R2 are fatty chains, R3 is an alkyl group and R4 is a protective group for alcohol functions. Another subject of the invention is the use of the intermediates of type F for converting same into intermediates of type G, by means of reduction in the presence of lithium borohydride. The G molecules are precursors that are known to make it possible to obtain sphingolipids or sphingomyelin.

NEW LIGANDS FOR TARGETING OF S1P RECEPTORS FOR IN VIVO IMAGING AND TREATMENT OF DISEASES

The present invention relates to novel compounds of formulae (I) and (II) which are useful in the prevention, treatment and diagnosis, in vivo diagnosis of diseases or disorders related to S1P receptors, in particular, in diseases which are connected to the regulatory function of sphingosine-1-phosphate (S1P) and its analogues, such as inflammation, pain, autoimmune diseases and cardiovascular diseases.

METHODS FOR THE SYNTHESIS OF SPHINGOMYELINS AND DIHYDROSPHINGOMYELINS

The present invention includes methods for the synthesis of sphingomyelins and dihydrosphingomyelins. The present invention also includes methods for the synthesis of sphingosines and dihydrosphingosines. The present invention further includes methods for the synthesis of ceramides and dihydroceramides.

METHODS FOR THE SYNTHESIS OF SPHINGOMYELINS AND DIHYDROSPHINGOMYELINS

The present invention includes methods for the synthesis of sphingomyelins and dihydrosphingomyelins. The present invention also includes methods for the synthesis of sphingosines and dihydrosphingosines. The present invention further includes methods for the synthesis of ceramides and dihydroceramides.

NEW LIGANDS FOR TARGETING OF S1P RECEPTORS FOR IN VIVO IMAGING AND TREATMENT OF DISEASES

The present invention relates to novel compounds of formulae (I) and (II) which are useful in the prevention, treatment and diagnosis, in vivo diagnosis of diseases or disorders related to S1P receptors, in particular, in diseases which are connected to the regulatory function of sphingosine-1-phosphate (S1P) and its analogues, such as inflammation, pain, autoimmune diseases and cardiovascular diseases.

The synthesis of pseudomycin C′ via a novel acid promoted side-chain deacylation of pseudomycin A

The γ hydroxyl present in the aliphatic side chain of the natural products pseudomycin A and C′ provided a unique handle for the pH dependent side-chain deacylation. Low pH reaction conditions were used to cleave the side chain with minimal degradation of the peptide core. The pseudomycin nucleus intermediate obtained from the deacylation of pseudomycin A was pivotal in the synthesis of novel side-chain analogues. A practical synthesis of a minor fermentation factor pseudomycin C′ and related analogues is reported.

Total synthesis of chiral 2-amino-1,3-diols

A method for the preparation of chiral 2-amino-1,3-diols is disclosed. The method involves four steps including performance of an aldol condensation with a chiral oxazolidinone on an aldehyde, treating the aldol condensation product with an alkali metal azide, treating the product with a borohydride reagent and reducing the azide to an amine.

Oxazolidinone aldol adduct

A oxazolidinone aldol adduct having the formula: STR1 wherein R is alkyl having 6 or more carbons or aryl; R1 is alkyl or aryl; R2 is alkyl, aryl or hydrogen; and X is a halogen atom or an azide. This aldol adduct is useful in a process for making 2-amino-1,3 diols.